Modified Kisspeptin Receptor Agonist as Novel Treatment of Non-Fatty Liver Disorder and Non-Alcoholic Steatohepatitis
TAK-448 protected insulin resistant, obese mice against the development of hepatic steatosis:
H& E showing fatty liver.
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder worldwide that can progress to steatohepatitis (NASH), the leading reason for liver transplants. In the U.S., there are...
Inventor(s): M. Moshmi Bhattacharya Babwah, Andy Babwah, Sally Radovick, Fredric Wondisford
Keywords(s): Diabetes & Metabolic Disorders, Peptides
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics